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           ABSTRACT 
 
A CROSS SECTIONAL STUDY ON THE PREVALENCE OF METABOLIC 
SYNDROME IN PATIENTS ON ANTIPSYCHOTIC MEDICATION. 
 
DEPARTMENT   : PSYCHIATRY  
NAME OF THE CANDIDATE : Dr.RANJITH P    
DEGREE AND SUBJECT  : MD PSYCHIATRY     
NAME OF THE GUIDE  : Dr.DEEPA BRAGANZA 
 
OBJECTIVES: 
 1.To study the prevalence of metabolic syndrome (MetS) as defined by the National 
Cholesterol Education Program's Adult Treatment Panel III(NCEP ATP III)  criteria and the 
International Diabetic Federation(IDF) criteria, in patients receiving antipsychotic 
medication. 
2. To assess the possible factors associated with metabolic syndrome in                  
patients meeting the criteria for metabolic syndrome. 
 
 
 
 
 
 
METHODS: 
A cross sectional study was done to measure the prevalence of metabolic syndrome in 
patients using antipsychotic medication. Participants, fulfilling the inclusion and exclusion 
criteria, were recruited from the outpatient facility in the department of Psychiatry, Christian 
Medical College, Vellore, after obtaining written informed consent. Socio demographic data, 
anthropometric variables, fasting blood glucose, HDL cholesterol and serum triglyceride 
values were measured. Prevalence of metabolic syndrome was calculated using IDF and 
NCEP ATP III criteria. 
 
RESULTS:   
Prevalence of metabolic syndrome was found to be 23%(IDF) and 26%(NCEP). Prevalence 
was 20% in males and 36% in females, with no significant statistical difference 
(pvalue=0.167).The prevalence of metabolic syndrome was higher in patients receiving 
antipsychotic medication for more than 1 year (p value= 0.311) and in patients having more 
than one year duration of illness (p value= 0.481). The individual components of metabolic 
syndrome also had a higher prevalence in females, however the differences were not 
statistically significant except abnormality in HDL cholesterol(p value 0.01). 
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Introduction 
 
Metabolic syndrome is a constellation of risk factors that when present in 
an individual, increases the risk for stroke, coronary artery disease and type2 
diabetes mellitus. Metabolic syndrome constitutes central obesity, elevated 
cholesterol and triglycerides, impaired glucose tolerance and high blood pressure. 
Presence of metabolic syndrome in an individual leads to increased morbidity and 
mortality. 
             
 Patients with schizophrenia and other mental illnesses are especially 
prone to develop metabolic syndrome, due to their life style factors, genetic 
predisposition and due to antipsychotic medication. The role of antipsychotic 
medication in producing metabolic syndrome in a patient is of major interest to 
clinicians these days, particularly in the context of the shift of use of second 
generation antipsychotics as first line medication in psychosis. 
 
There are various risk factors for the development of metabolic syndrome 
in people. They include poor diet habits, lifestyle factors, smoking and alcohol 
use, diabetes, chronic illnesses and genetic vulnerability. Prevalence of metabolic 
syndrome is high in people who have first degree relatives having diabetes 
mellitus or dyslipidemia.  
 
 Prevention is an important part of the management of metabolic 
syndrome as it helps to reduce the risk of severe cardiovascular morbidity and 
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other metabolic abnormality. Weight reduction, physical exercises are the key 
strategies to reduce the risk of metabolic syndrome. Pharmacological 
interventions are used only when the above strategies fail, and may not play a 
significant role. 
             
 Almost a quarter of the world population is estimated to have metabolic 
syndrome and is prone to complications related to it. Studies have shown that the 
prevalence of metabolic syndrome is higher in patients taking antipsychotic 
medications compared to the general population.  
 
In this study we set out to measure the prevalence of metabolic syndrome 
in a sub group of patients attending a psychiatric tertiary care centre, and to look 
at the possible factors that are associated with, and which might predict 
development of metabolic syndrome in patients on antipsychotic medication. 
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Review Of Literature 
 
Metabolic syndrome  
Metabolic syndrome is a group of conditions - increased blood pressure, 
elevated blood sugars, deranged cholesterol and accumulation of excess fat 
around the waist and abdomen, that when present together, can increase the 
chance of having heart disease, stroke and diabetes mellitus, thus increasing 
morbidity and mortality. These factors can present in a person in varying levels.  
   
Metabolic syndrome also has various other names like syndrome X, 
Reavens syndrome, cardio-metabolic syndrome and insulin resistance syndrome. 
Metabolic syndrome has emerged as a major factor causing morbidity and 
mortality in this age of non-communicable diseases. Life style factors, nutrition 
and genetic vulnerability all contribute the development of this dreaded 
complication.  
 
The term metabolic syndrome was first used by Hanefield and Leonardt in 
1981. Reaven in 1988 proposed the name syndrome X  to denote a group of 
conditions like hyperinsulinemia, glucose intolerance, and elevated  cholesterol 
which were important in causing coronary artery disease. The term “deadly 
quartet” was used by Kaplan for the association of hypertension, obesity, glucose 
intolerance and hypertriglyceremeia in which hyperinsulinemia has a pathogenic 
association(1). 
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Components of metabolic syndrome 
 
 
CHD- Coronary heart disease 
 
 
PATHOPHYSIOLOGY 
 
Insulin resistance     
Insulin, secreted by the pancreas is a very potent anabolic hormone. It has 
effects on metabolism of lipid and protein, has a role in amino acid and ion 
transport, and affects cell cycle and cell differentiation(2). Insulin resistance is 
believed to be the major underlying pathophysiology for the development of 
metabolic syndrome. This is caused by the inability of the target organs to 
effectively utilize insulin, with a resultant hyperinsulinemia (3). This 
hyperinsulinemia may help to compensate some of the functions of insulin like 
maintaining normoglycemia, but causes over expression of insulin action in some 
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tissues. This overactivity of insulin in some tissues associated with insulin 
resistance in some tissues leads to the development of metabolic syndrome(4). 
There are several mechanisms proposed for the insulin resistance which include 
receptor, pre receptor and post receptor mechanisms. 
 
Non esterified fatty acids are also believed to have role in the development 
of insulin resistance. Adipose tissue deposits in abdomen releases non esterified 
fatty acids into the blood stream. This in turn gets overloaded in the liver and 
muscles thereby leading to insulin over activity and resistance in these tissues. 
Lipoprotein lipase is an enzyme which breaks down lipoproteins to release free 
fatty acids. The action of lipoprotein lipase is stimulated by insulin. Insulin also 
inhibits lipolysis in adipose tissue. When insulin resistance develops, the 
inhibitory effect of insulin to lipolysis of adiposites reduces and more free fatty 
acids are produced. These free fatty acids in turn cause production of toxic 
materials inside the cells, further increasing the insulin resistance. This vicious 
cycle results more and more lipolysis and insulin resistance (5). 
 
Role of obesity  
The worldwide obesity epidemic has a major role in the increase in the 
prevalence of metabolic syndrome (6). Recent studies have shown that the central 
obesity appears before the onset of other metabolic syndrome factors and that 
weight reduction in the initial stages has an important role in the prevention of 
metabolic syndrome (7). Adipose tissue acts, not merely as a storage site for 
triglycerides. Recently it has been shown that it has other complex roles like 
secretion of adipokines. And these adipokines are reported to significantly 
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contribute to the development of metabolic syndrome (8).  High levels of free 
fatty acids in the blood leads to accumulation of the same in liver thereby causing 
fatty liver.(9)   
 
 Hypertension  
 All the elements of metabolic syndrome, including insulin resistance, 
obesity,     and dyslipidemia, likely have a role in the pathogenesis of 
hypertension. However obesity is believed to play a major role in the 
pathogenesis of metabolic syndrome(10). The Framingham Heart Study has 
shown that hypertension may be due to excess body fat and that it is so in 78% of 
men and 65% of women with hypertension. Increased retention of sodium is 
believed to be another causative factor in the development of hypertension in 
metabolic syndrome. Increased sodium retention by the kidneys, results in 
increased fluid volume, which causes hypertension. 
 
Dyslipidemia 
Elevation of triglycerides and lower level of HDL cholesterol are the 
major findings in metabolic syndrome. Insulin resistance and hyperinsulinemia 
leads to conversion of free fatty acids to triglycerides. 
Low HDL is always an accompaniment of obesity. High triglycerides are a major 
cause for decreased HDL cholesterol. An increase in triglycerides, through 
various mechanisms, causes a reduction in the size of HDL particles, which are 
more readily metabolized. The smaller HDL particles are less effective in 
combating atherogenesis which, in turn, increases the risk of cardiovascular
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diseases. Due to unknown mechanisms the level of HDL cholesterol is low in 
some individuals with normal level of triglyceride level. 
 
In metabolic syndrome the level of LDL cholesterol is usually normal. 
However the existing LDL molecules are denser and smaller, which in turn is 
associated with atherogenesis. 
Elevated LDL cholesterol also contributes to endothelial injury and resultant 
atherogenesis. 
 
Inflammation 
Chronic, subclinical inflammation is often seen associated with metabolic 
syndrome(5).  Inflammatory mediators are seen to increase the risk of 
cardiovascular events and also believed to be one of the causes of insulin 
resistance. There are recent data to show that, obesity itself is a pro-inflammatory 
state. Inflammatory mediators like C-reactive protein, tumour necrosis factor 
alpha, Interleukin-6 and others are increasingly seen associated with obesity. A 
study on inflammatory mediators and inflammatory mediators revealed that C- 
reactive protein is strongly associated with obesity(11). Researchers also have 
argued the cause for including C- reactive protein as a criterion to diagnose 
metabolic syndrome due to its strong association with the problem (12). 
 
Macrophages present in the adipose tissue can act as a source of pro-
inflammatory markers. 
Oxidative stress is believed to be the cause of inflammatory reaction in the 
adiposites(13).  
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Prothrombotic state 
Prothrombotic state is also not included in the current definitions of 
metabolic syndrome despite its significant association with obesity and insulin 
resistance. People with metabolic syndrome have very high levels of plasma 
plasminogen activator inhibitor, which shows a dysfunctional fibrinolytic 
activity(14). Elevated levels of fibrinogen are also seen in metabolic syndrome. 
 
Definitions and Diagnosis 
Currently, there are several definitions to diagnose metabolic syndrome. 
Among them, those of the WHO, the International Diabetes Federation(15)  and 
the revised National Cholesterol Education Program are the  widely used 
definitions. 
World Health Organisation (WHO) 
The World Health Organisation attempted to standardise the criteria in 
1988. Insulin resistance was viewed as a must have component to diagnose 
metabolic syndrome. To diagnose metabolic syndrome, insulin resistance was 
identified by the criteria given below. In addition, two other risk factors, listed 
below, were required. 
Insulin resistance, identified by one of the following: 
 Type 2 diabetes 
 Impaired fasting glucose 
 Impaired glucose tolerance 
 or for those with normal fasting glucose levels (<6.1 mmol/L), glucose 
uptake below the lowest quartile for the background population under 
investigation under hyperinsulinemic, euglycemic conditions 
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Plus any two of the following: 
 Antihypertensive medication and/or high blood pressure (≥140 mm Hg 
systolic or ≥90 mm Hg diastolic) 
 Plasma triglycerides ≥1.7 mmol/L 
 HDL cholesterol <0.9 mmol/L in men or <1.0 mmol/L in women 
 BMI >30 kg/m
2
 and/or waist:hip ratio >0.9 in men, >0.85 in women 
 Urinary albumin excretion rate ≥20 μg/min or albumin:creatinine ratio 
≥3.4 mg/mmol 
One disadvantage of the above criteria is that special testing of blood 
glucose other than the routine clinical assessment may be required to diagnose 
metabolic syndrome. 
European Group for the Study of Insulin Resistance (EGIR) 
The European Group for the Study of Insulin Resistance (1999) stated that it 
is difficult to measure insulin resistance in diabetic patients, while fasting insulin 
values were considered as a reliable measure of insulin resistance in non diabetic 
patients. The EGIR recommended that metabolic syndrome can be diagnosed by 
top 25% of the fasting insulin values among non-diabetic individuals and two or 
more of the following:  
 Hypertension: blood pressure ≥ 140/90 mmHg or antihypertensive 
medication 
 Fasting plasma glucose ≥ 6.1 mmol/L 
 Central obesity: waist circumference ≥ 94 cm (male), ≥ 80 cm (female) 
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 Dyslipidemia: TG ≥ 2.0 mmol/L and/or HDL-C < 1.0 mmol/L or treated 
for dyslipidemia 
National Cholesterol Education Program Adult Treatment Panel III (2001) 
(NCEP) 
The NCEP ATPIII introduced the concept and diagnostic guidelines for 
metabolic syndrome in 2001. It diagnoses metabolic syndrome in an individual if 
3 or more of the following 5 are present. 
 Blood pressure equal to or higher than 130/85 mmHg 
 Fasting blood sugar (glucose) equal to or higher than 110 mg/dL 
 Large waist circumference (length around the waist):  
o Men - 102 cm or more 
o Women – 88 cm or more 
 Low HDL cholesterol:  
o Men - under 40 mg/dL 
o Women - under 50 mg/dL 
 Triglycerides equal to or higher than 150 mg/dL 
The advantage of the NCEP ATPIII criteria is that it is more user friendly and 
it gives both epidemiologists and clinicians valid, reliable and simple criteria to be 
used both in clinical and research settings.   
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International Diabetes Federation (IDF) 
The International Diabetes Federation introduced the concept of metabolic 
syndrome and its criteria in 2006. IDF places more importance on the abdominal 
obesity as the other features of metabolic syndrome, including insulin resistance, 
are indirectly linked to the abdominal obesity. IDF also introduced ethnic specific 
values for the diagnosis of metabolic syndrome. 
According to IDF metabolic syndrome is diagnosed if somebody is having 
Central obesity (defined as waist circumference
 
with ethnicity-specific values - 
≥94 cm for Europoid men and ≥ 80 cm for Europoid women, ≥ 90 cm for men 
and ≥ 80 cm for women  for those of south and south east Asian , Japanese and 
ethnic south and central American origins) 
And any two of the following: 
 Raised triglycerides -  > 150 mg/dL (1.7 mmol/L), or specific treatment 
for this lipid abnormality 
 Reduced HDL cholesterol- < 40 mg/dL (1.03 mmol/L) in males, < 
50 mg/dL (1.29 mmol/L) in females, or specific treatment for this lipid 
abnormality 
 Raised blood pressure (BP) -systolic BP > 130 or diastolic BP >85 mm 
Hg, or treatment of previously diagnosed hypertension 
 Raised fasting plasma glucose (FPG) - >100 mg/dL (5.6 mmol/L), or 
previously diagnosed type 2 diabetes 
 If FPG is >5.6 mmol/L or 100 mg/dL, an oral glucose tolerance test is 
strongly recommended, but is not necessary to define presence of the 
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syndrome. 
If BMI is >30 kg/m², central obesity can be assumed and waist 
circumference does not need to be measured. 
All the four above mentioned criteria defining the metabolic syndrome using 
different criteria are more or less similar conceptually though there are some 
striking disparities. One major criticism of the WHO criteria is that it has included 
type2 diabetes as a criterion rather than reserving the diagnosis of metabolic 
syndrome to those who are at risk of developing diabetes mellitus. Also, impaired 
glucose tolerance measured by oral glucose tolerance test is consider to be 
impractical and leading to more costs, without much of an added benefit in 
predicting cardiovascular risk.  
 
The NCEP criteria are criticized for the same reason as WHO criteria for 
including diabetes in the criteria. Also, it fails to identify those on treatment for 
hypertension or dyslipidemia when defining the criteria.  
 
The strength of IDF is that it provides pragmatic waist circumference with 
ethnic specific values as a criterion. It also considers treatment for hypertension 
and dyslipidemia as criteria. However, like other systems mentioned above, IDF 
also fails to exclude diabetes as a criterion. 
          
Considering the above pitfalls with the definitions, Resin and Alpert in 2005 
proposed a better definition for metabolic syndrome which takes into account the 
major differences among the existing definitions. They proposed abdominal 
obesity as a major component based on its consistent association with metabolic 
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syndrome parameters. They also included ethnic specific cut off for waist 
circumference as defined by IDF. Previous diagnosis of dyslipidemia and 
hypertension also found place in the definition. They proposed a lower level of 
100mg/dl for the fasting glucose value as recommended by the American 
Diabetes association. They also recommend including the WHO 
microalbuminuria criteria considering the fact that it predicts the development of 
chronic kidney disease. 
 
Prevalence of metabolic syndrome in general population  
A study has shown that the prevalence of metabolic syndrome varies from 
8% in India to 24% in United States of America(5). The prevalence among 
women varies from as low as 7% in France to as high as 43% in Iran(5). A study 
in China has shown the prevalence of metabolic syndrome was higher in women 
compared to men in all age groups. There is age related increase in the prevalence 
of metabolic syndrome in United States in both men and women.  
 
A recent assessment by the International Diabetic federation has found 
that the one quarter of world’s population has metabolic syndrome and is prone to 
risk of cardio metabolic morbidity. Studies have shown variation in the 
prevalence of metabolic syndrome in different races and ethnic groups and among 
men and women(16) 
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World-wide prevalence of metabolic syndrome -Cameroon et al (17) 
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Prevention and treatment 
The prevalence of metabolic syndrome is very high in the general 
population. At least a quarter of the world population has metabolic syndrome. 
Prevention of development of metabolic syndrome should be a priority in clinical 
practice. Identifying the risk factors of metabolic syndrome is an important 
direction in prevention of its development and complications(18). The treatment 
strategies include weight loss, lifestyle changes, diet modifications and 
appropriate use of pharmacological agents (19). 
 
Educational intervention should be patient centered and should be focused 
on eliciting patient views on the knowledge of metabolic syndrome and the role of 
exercise and diet in reducing this complication.  Clinicians and educators should 
be able to provide patients with short term or long term goals and address the 
barriers to change. Pharmacological strategies should be considered only if the 
non pharmacological strategies fail to adequately contain the problem(19). 
 
Several studies have repeatedly stressed the role of weight reduction. They 
have recommended a weight loss of at least 10% during the first 6 months to a 
year and to continue weight losing strategies until the BMI is less than 25 (9).  
The pharmacological strategies to reduce weight include two main classes of 
drugs, suppressants of appetite and inhibitors of nutritional absorption. 
Sibutramine and phentermine derivatives, that when taken in the early morning, 
reduce the appetite in the afternoon and evening. The only nutrient absorption 
inhibitor currently available in the market is orlistat, which is found to prevent up 
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to 30% absorption of fat. It is recommended for use as a single agent at a time to 
reduce weight (20). 
 
Weight loss programs are usually successful only if a regular exercise 
program is also added along with it. Additionally regular exercise independently 
reduces the risk factors for metabolic syndrome(5). 
 
Mental illness and metabolic syndrome 
The life expectancy of people with severe mental illnesses like 
schizophrenia, is lower than that of the general population(21–24). Their 
mortality is 2 to 3 times more  than the general population, and the mortality gap 
is increasing in the recent decades (25). The risk of dying due to a cardiovascular 
disease is nearly twice in people with severe mental illness(22–26).  
Knowledge regarding the alarming nature of the physical comorbidity and 
mortality due to the same has led in recent decades to a rising concern about 
physical comorbidity in people with severe mental illness (27–29). In spite of 
significant somatic comorbidities, the access to quality health care is very poor for 
patients with severe mental illness(30).   
The cardio metabolic risk factors are attributable to lifestyle, poor diet, 
and sedentary habits, in patients with severe mental illness. There is recent 
increase in awareness among clinicians regarding the role of antipsychotic agents 
in causing metabolic syndrome (27–29). And these metabolic changes are 
dependent on the dose of the antipsychotic drug (31) . 
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Table: Estimated prevalence and relative risk (RR)  of modifiable cardiovascular 
disease risk factors in schizophrenia and bipolar disorder compared to the general 
population(32) . 
 Estimated prevalence 
,%(RR) 
 
Modifiable risk factors Schizophrenia Bipolar disorder 
Obesity 45-55(1.5-2) 21-49(1-2) 
Smoking 50-80(2-3) 54-68 (2-3) 
Diabetes 10-15(2) 8-17(1.5-2) 
Hypertension 19-58(2-3) 35-61(2-3) 
Dyslipidaemia 25-69(≤5) 23-38(≤3) 
Metabolic syndrome 37-63(2-3) 30-49(1.5-2) 
 
In the general population, the presence of Metabolic syndrome is a strong 
predictor of Cardiovascular disease , mortality and diabetes mellitus (33)  . 
The concept of Metabolic syndrome is increasingly being  recognised in 
psychiatric literature and  this has  helped in creating awareness among 
psychiatrist about the importance of assessing cardiovascular disease risk in 
patients being prescribed antipsychotics (34,35) 
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Table: Second generation antipsycotic agents and metabolic abnormalities 
  Antipsychotic Weight gain Risk for diabetes Worsening 
   lipid profile 
Clozapine +++ + + 
Olanzapine +++ + + 
Risperidone ++ ? ? 
Quetiapine ++ ? ? 
Aripiprazole ± No report No report 
Ziprasidone ± No report No report 
Amisulpride ± No report No report 
 
In the recent study, the Clinical Antipsychotic Trials of Intervention 
Effectiveness (CATIE), around one third of patients met NCEP criteria for 
metabolic syndrome at baseline(36,37).  Among them 88% of patients with 
dyslipidaemia, 62% patients with hypertension and 38% of those with diabetes 
were not receiving treatment(37). There was significant difference between 
individual  antipsychotic agents in causing adverse effects on weight, lipids, and 
glucose metabolism(37,38).  
In a recent study comparing  metabolic syndrome in patients diagnosed 
with schizophrenia in 2000-2006 to  those who were diagnosed with 
schizophrenia in 1984-1995, second generation antipsychotic medication is 
implicated in causing twice as much of metabolic syndrome compared to first 
generation antipsychotic drugs(39). 
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While lifestyle factors, psychosis related factors and antipsychotic 
medication are commonly implicated as the causal factors of metabolic syndrome 
in schizophrenia, recent studies have explored the possible genetic causes for the 
metabolic syndrome in this sub group of patients (35, 36). Studies have shown 
that there is an increased liability for patients with schizophrenia for developing 
metabolic syndrome even without taking antipsychotic medication, as well as 
increased risk for developing diabetes mellitus in first degree relatives (42)   
There is also evidence for elevated blood sugar levels, visceral adiposity, and 
increased cortisol levels in patients before starting treatment with antipsychotic 
drugs(43,44).  A higher vulnerability for developing metabolic syndrome in 
schizoaffective disorder compared to bipolar disorder and schizophrenia is shown 
in a recent study (45) . 
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Table: Prevalence of metabolic syndrome in people with schizophrenia 
Study Country N Mean age %MetS 
Heiskanen et al 
(78) 
Finland 35 44.5 37.1 
Almeras et al 
(62) 
Canada 42 31.7 33.0 
 Canada 45 28.4 11.0 
Basu et al (65) USA 33 44.5 42.4 
Cohn et al (68) Canada 240 42.7 44.6 
Kato et al (80) USA 48 40.3 63.0 
Straker et al 
(96) 
USA 89 39.8 29.2 
Meyer et al 
(83) 
USA 1231 42.8 35.8 
McEvoy et al 
(82) 
USA 342 39.8 40.9 
  92 44.2 56.2 
Saari et al (88) Finland 31 31.0 19.4 
Correll et al 
(69) 
USA 367 42.9 37.3 
De Hert et al 
(71) 
Belgium 430 36.5 32.3 
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Table: Prevalence of metabolic syndrome in people with schizophrenia(contd) 
Study Country N Mean age %MetS 
Lamberti et al 
(81) 
USA 93 34.4 53.8 
Meyer et al 
(84) 
USA 80 49 51.2 
Bobes et al 
(66) 
Spain 1452 40.7 24.6 
Correll et al 
(70) 
USA 294 43.6 34.3 
De Hert et al 
(73) 
Belgium 208 33.7 27.9 
  23 33.7 13 
  31 33.7 9.7 
  25 33.7 56 
  54 33.7 33.3 
  25 33.7 32 
  50 33.7 24 
L’Italien et al 
(79) 
USA 155 41.4 25.8 
  267 40.7 19.9 
  373 37.7 41.6 
  380 37.6 27.9 
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Table: Prevalence of metabolic syndrome in people with schizophrenia (contd) 
Study Country N Mean age %MetS 
Mulder et al 
(85) 
Netherlands 112 36 25 
Sicras-Mainar 
et al 
Spain 742 55.1 27 
(94)  57 37.5 35 
Srisurapanont 
et al 
Thailand 38 53.7 36.2 
(95)  44 44.3 31.8 
Suvisaari et al 
(97) 
Finland 108 34.6 34 
Teixeira and 
Rocha 
Brazil 122 23.1 5.7 
(98)  122 26.8 13.1 
Cerit et al (67) Turkey 108 21.9 5.6 
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Table: Incidence of metabolic (MetS) in people with schizophrenia  
 
Study Country N Mean age %MetS 
De Hert et al 
(71) 
Belgium 31 36.7 61.3 
   36.7 29 
Attux et al (64) Brazil 44 26.3 6.8 
De Hert et al 
(72) 
Belgium 155 33.7 18.7 
  16 33.7 6.3 
  16 33.7 0 
  20 33.7 45 
  45 33.7 24.4 
  21 33.7 19.1 
  37 33.7 10.8 
L’Italien et al 
(79) 
USA 91 41.4 14.3 
  151 40.7 5.3 
  212 37.7 27.4 
  198 37.6 15.7 
Saddichha et al 
(89) 
India 30 26.9 27.5 
Srisurapanont 
et al (95) 
Thailand 35 34.7 20 
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Study Country N Mean age %MetS 
De Hert et al 
(74) 
Belgium 122 26.8 9.8 
  108 25.1 27.8 
  8 25.1 12.5 
  10 25.1 0 
  12 25.1 50 
  34 25.1 41.3 
  24 25.1 12.6 
  20 25.1 10.2 
Meyer et al 
(84) 
USA 164 40.9 34.8 
   40.9 43.9 
  147 40.9 30.6 
   40.9 30.6 
  143 40.9 37.8 
   40.9 37.1 
  77 40.9 37.7 
   40.9 29.9 
  129 40.9 37.2 
   40.9 38 
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The propensity of antipsychotic drugs to induce weight gain is seen partly 
as the cause for metabolic syndrome. All antipsychotic drugs cause weight gain, 
however the propensity to cause clinically relevant weight gain(>7% increase) 
varies between different antipsychotic agents(46). Studies have shown a link 
between the receptor profile of antipsychotic agents and their ability to cause 
metabolic changes and weight gain. Some authors link the receptor profile of 
antipsychotics to their differential liability to induce weight gain and other 
metabolic changes (44,46).  Effect on muscarinic receptors as an antagonist could 
lead to increased weight gain. Antagonistic effect on the dopamine reward system 
can lead to increased appetite and thus increased weight gain.(47).Studies have 
also shown the irreversibility of antipsychotic agents on weight gain even after 
discontinuation of antipsychotic drugs possibly due to a direct effect on pancreatic 
function(42,44,46). 
Some recent studies show that children and adolescents  are more prone to 
metabolic side effects and weight gain on antipsychotic medication when 
compared to adult subjects (48,49). 
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GUIDELINES FOR SCREENING AND MONITORING  
Prevention of development of metabolic syndrome should be a priority 
while starting antipsychotic medication. In order to prevent this complication, diet 
modification and lifestyle interventions should be started along with the 
commencement of treatment with antipsychotics. 
A failure to provide appropriate and effective general health care to 
mentally ill patients is due to a lack of consensus regarding the responsibility 
towards the patient. Usually, the general medical needs of the mentally ill are 
neglected and the psychiatrist’s focus is mainly on the efficacy of antipsychotics 
on the psychotic symptoms. 
Though there are many national and international guidelines for 
monitoring metabolic syndrome and other general health indicators, these are 
rarely used in the routine care of the patients(50–52). 
Assessment of cardio metabolic risk profile is important before the 
commencement of treatment with antipsychotic drugs. The sensitivity of the 
combination of fasting glucose and waist circumference  in identifying patients 
with metabolic syndrome, is as high as 100%. Before start of treatment, the 
cardio-metabolic risk profile of a patient should be assessed (53). 
Lifestyle interventions, physical exercises, and diet modification should be 
started early to prevent complications(24). The lowering of risk while 
successfully instituting the above measures is very significant. A 30% reduction  
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in  cardiovascular disease risk is seen upon reducing the cholesterol levels by 
10%. A 6% lowering of blood pressure leads to a 15% reduction in the 
cardiovascular risk. Similarly a 50 to 70 % reduction in cardiovascular disease 
prevalence is seen with cessation of smoking. A 20 minutes brisk walk a day and 
keeping the body mass index below 25 helps to reduce the cardiovascular disease 
risk by 30 to 50% (24). There is growing evidence to support the effectiveness of 
lifestyle interventions to reduce the risk of cardiovascular and metabolic effects in 
mentally ill patients. 
  The role of regular physical activity in reducing the risk of metabolic side 
effects and cardiovascular disease risk is undisputed (54). Regular physical 
activity helps in the prevention of obesity, hypertension, dyslipidemia and 
diabetes (55,56). Therefore, regular physical exercise should be included in the 
lifestyle modification intervention in schizophrenia. Though there are no strict 
guidelines to recommend the type and duration of physical activity in patients 
with schizophrenia, 30 minutes walk at least 5 days a week will be sufficient to 
significantly reduce the metabolic risk. While selecting the physical activity 
attention should be given to the patient’s personal preference and  attitude 
towards physical activity (54,57).  
Switching to a different antipsychotic drug that has reduced potential to 
cause metabolic side effects is an important strategy if a patient develops 
metabolic syndrome with a particular antipsychotic. Instituting appropriate 
measures to reduce blood pressure, control blood glucose or to lower cholesterol 
and triglycerides should be considered along with switching antipsychotic drug. 
While doing this, consultation with a specialist should be done if it is appropriate. 
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There is recent evidence to suggest that statins are effective and safe in patients 
with schizophrenia who are exposed to antipsychotics. However statins have little 
role in reversing the metabolic syndrome once it  has developed  (58,59). 
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AIMS AND OBJECTIVES 
 
 Primary Objective 
 To study the prevalence of metabolic syndrome (MetS) as defined by the 
National Cholesterol Education Program's Adult Treatment Panel III criteria and 
the International Diabetic Federation criteria, in patients receiving antipsychotic 
medication. 
 
 
Secondary objective 
 To assess the possible factors associated with metabolic syndrome in                  
patients meeting the criteria for metabolic syndrome. 
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METHODOLOGY 
 
Setting:  
The study was conducted in the Department of Psychiatry, Christian 
Medical College, Vellore. This is a 122 bedded tertiary care centre offering 
inpatient and outpatient treatment for patients with psychiatric illness. The 
hospital caters to patients from various parts of the country. 
 
The facilities in the department include a well equipped outpatient 
department inpatient facility, nursing service, occupational therapy, pharmacy 
services,laboratory services and emergency services. 
 
The outpatient department functions 6 days in a week and both new and  
review patients are seen. Emergency care is provided 24 hours in a day. 
 
This institution has the facilities of a tertiary referral centre, but serves in  
addition as the nearest psychiatric centre for a radius of approximately 150 miles. 
The department has four units, two serving adult clients, one for children and 
adolescents, and one for rehabilitation services. Approximately 11000 new 
patients and 90000 review patients are seen in a year in this centre. On an average 
1000 patients are provided inpatient treatment in an year. 
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 Participants:  
Participants for the study were recruited from the outpatient facility in the 
department of psychiatry. Patients attending the outpatient facility were screened 
using the inclusion and exclusion criteria. Patients who met these were given an 
information leaflet in their own language and given an explanation of the possible 
risks and benefits of the study. Those who gave written consent to be included in 
the study were recruited. 
 
Inclusion Criteria: 
 Age above 18 years 
 On stable dose of antipsychotic drugs for the last 3 months or more 
  Exclusion Criteria: 
 Patients with alcohol abuse or dependence or organic conditions 
 History of diabetes or hypertension before starting antipsychotic drugs 
 On other medications like mood stabilizers, which may have confounding 
effect on the outcome variable. 
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Variables:  
 
The variables assessed included age, gender, individual metabolic 
parameters like waist circumference, fasting blood sugar, HDL cholesterol, 
triglycerides, duration of illness and duration of antipsychotic use. 
 
Data Sources/measurement:   
Patients attending the psychiatric OPD were screened. Those meeting the 
inclusion criteria were enrolled into the study after obtaining written informed 
consent. 
Data collection was begun after approval by the Institutional review board. 
Data was collected from May 2012 to October 2012. 
 
Demographic data including age, sex, occupational and marital status, 
family history of medical and mental illness were collected from the patient and 
the relative. Subsequently blood pressure, height, body weight and waist 
circumference were measured and documented. Patients were asked to do fasting 
blood glucose and fasting triglycerides, and HDL cholesterol during the next 
hospital visit. If the patients had done the blood tests (AC, HDL, Triglycerides) 
within last one month at the time of recruitment as part of their routine care, the 
same values were used for the study and blood tests were not repeated.  
 
Prevalence of metabolic syndrome was assessed using NCEP ATPIII 
criteria and International Diabetic Federation criteria.  
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Sample size:  
Sample size was calculated using a previous study which estimated the 
prevalence of metabolic syndrome as 32%  (60). Sample size required to detect a 
prevalence of 32% with a 10% margin of error for 95% CI was 90. The following 
assumptions were made for the calculation of the sample size: 
Prevalence    = 32% 
Margin of error  = ±10 
Confidence level  = 95% 
Total required sample size = 90 
 
Quantitative variables:  
Quantitative variables included waist circumference, blood glucose, HDL 
and triglyceride values, duration of illness and duration of antipsychotic use. 
 
Statistical methods:  
The statistical analysis was performed using Stata (SE 10.1 version). 
Results were expressed as mean ± standard deviation (SD). Pearson’s chi-square 
test was applied to test the relationship of categorised independent and dependent 
variables. 
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RESULTS 
 
A total of 83 patients were screened for the study. They were referred by 
colleagues based on the inclusion and exclusion criteria. 2 people declined 
consent as they were living far away from hospital and expressed inability to do 
blood tests at the hospital. A total of 81 patients were recruited into the study after 
obtaining written informed consent. 57 subjects followed up for giving fasting 
blood sample and 3 subjects had already done blood tests in the last one month. 
Hence the analysis and results are based on data for 60 participants.  
Flow chart 
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Out of the 60 subjects, 35 were male 25 were female. The mean age of the 
participants was 36 years. 19 subjects were illiterate, 30 had school education and 
11 subjects had undergone graduate training.       
 
Distribution of participants according to marital status 
 
Marital status   Number    
of participants 
percentage 
Single 24 
 
40 
Married 30 
 
50 
Separated/widow 6 
 
10 
Total 60 
 
100 
 
  
Out of 60, 24 subjects were unmarried , 30 were married and 6 were either 
widowed or separated from the partner. 
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Distribution based on gender 
 
Gender 
 
No of participants Percentage 
Male 
 
35 58 
Female 
 
25 42 
Total 
 
60 100 
 
35 (58%) were male and 25(42%) were female. 
37 
 
 
sex
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Distribution based on employment status 
 
Employment 
Status 
No of participants Percentage 
Unemployed 
 
52 87 
Employed 
 
8 13 
Total 
 
60 100 
 
52 (87%) were unemployed and 8(13%) were employed. 
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Distribution based on educational level 
 
Educational status Number of participants Percentage 
Illiterate 19 31 
Primary 15 25 
Middle school 15 25 
High school 3 5 
Intermediate 2 3.3 
Graduate 5 8.3 
Post graduate 1 1.7 
Total 60 100 
 
39 
 
 
 
 
educational status
pg
graduate
intermediate
high school
middle
primary
illiterate
 
 
 
 
 
 
 
 
 
 
 
 
 
40 
 
 
 
 
Distribution of means of variables 
 
Variable Mean Standard 
Deviation 
Minimum 
value 
Maximum 
Value 
Age 
 
36 years 11 20 65 
Waist 
circumference 
87 cm 10 65 112 
Blood pressure –
systolic 
119 mmHg 11 100 150 
Blood pressure-
diastolic 
76 mmHg 6 70 90 
Fasting blood 
sugar 
92 mg/dL 15 71 185 
HDL cholesterol 
 
41mg/dL 10 26 73 
Triglycerides 
 
145  mg/dL 90 39 535 
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Distribution according to criteria satisfying metabolic syndrome definition.
   In the tables listed below, each variable is shown depending on whether 
they satisfied the criteria for metabolic syndrome or not. The number of 
participants are divided according to this. 
 
Distribution according to waist circumference  
 
Waist 
Circumference 
(wc) 
Number of 
participants(IDF) 
Number of 
participants(NCEP 
ATP III) 
MetS(wc)+ 
 
33 (55%) 18(30%) 
MetS(wc)-  
 
27(45%) 42(70%) 
Total 
 
60(100%) 60(100%) 
 
MetS(wc)+   Number of participants satisfying criteria for MetS  
MetS(wc)-    Number of participants not satisfying the criteria 
 
42 
 
 
The mean value of weight circumference was 87 cm with a standard 
deviation of 10. Out of 60 subjects, 33 (55%) were above the specified value 
according to IDF and 18 (30%) met the criteria according to  NCEP ATP III. 
 
Distribution according to fasting blood sugar 
 
Fasting blood 
sugar (ac) 
Number of 
participants(IDF) 
Number of 
participants(NCEP 
ATP III) 
MetS(ac)+ 
 
8(13%) 3(5%) 
MetS(ac)-  
 
52(87%) 57(95%) 
Total 
 
60(100%) 60(100%) 
 
MetS(ac)+   Number of participants satisfying criteria for MetS  
MetS(ac)-    Number of participants do not satisfying the criteria 
The mean value of fasting blood sugar was 92 with a standard deviation of 15.  
8(13%) participants met the criteria according to IDF and 3(5%) met the criteria 
according to NCEP ATP III. 
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Distribution according to HDL Cholesterol 
 
HDL 
Cholesterol 
(hdl) 
Number of 
participants(IDF) 
Number of 
participants(NCEP 
ATP III) 
MetS(hdl)+ 
 
37(62%) 37(62%) 
MetS(hdl)-  
 
23(38%) 23(38%) 
Total 
 
60(100%) 60(100%0 
 
MetS(hdl)+   Number of participants satisfying criteria for MetS  
MetS(hdl)-    Number of participants do not satisfying the criteria 
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The mean value of HDL Cholesterol was 41mg/dL with a standard deviation of 
10.  Out of 60 subjects, 37 (62%) subjects met the criteria according to IDF and   
NCEP ATP III. 
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Distribution according to Triglyceride (tg) value.  
 
Triglycerides 
(tg) 
Number of 
participants(IDF) 
Number of 
participants(NCEP 
ATP III) 
MetS(tg)+ 
 
25 (42%) 25(42%) 
MetS(tg)-  
 
35(58%) 35(58%) 
Total 
 
60(100%) 60(100%) 
 
MetS(tg)+   Number of participants satisfying criteria for MetS  
MetS(tg)-    Number of participants do not satisfying the criteria 
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 The mean value of Triglycerides was 146 cm with a standard deviation of 90. 
Out of 60 subjects, 25(42%) were above the specified value according to IDF and 
NCEP ATP III. 
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Distribution according to blood pressure 
 
Blood pressure 
(bp) 
 
Number of 
participants(IDF) 
Percentage  
(IDF) 
Number of 
participants(NCEP 
ATP III) 
Percentage 
(NCEP ATP 
III) 
MetS(bp)+ 
 
15 25 15 25 
MetS(bp)-  
 
45 75 45 75 
Total 
 
60 100 60 100 
 
MetS(bp)+   Number of participants satisfying criteria for MetS  
MetS(bp)-    Number of participants do not satisfying the criteria 
 
The mean value of HDL Cholesterol was 41mg/dL with a standard 
deviation of 10.  Out of 60 subjects, 37 (62%) subjects met the criteria according 
to IDF and   NCEP ATP III. 
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Prevalence of metabolic syndrome. 
 
Metabolic 
Syndrome 
(MetS) 
Number of 
participants(IDF) 
Number of 
participants(NCEP 
ATP III) 
MetS+ 
 
14 (23%) 16(27%) 
MetS-  
 
46(77%) 44(73%) 
Total 
 
60(100%) 60(100%) 
 
MetS +   Number of participants satisfying criteria for MetS  
MetS -    Number of participants do not satisfying the criteria 
 
The prevalence of metabolic syndrome calculated separately with 
International Diabetic Federation(IDF) criteria and US National Cholesterol 
Education Program Adult Treatment Panel III (NCEP ATP III) criteria 
 
Prevalence of metabolic syndrome according to IDF = 14 (23%) 
Prevalence of metabolic syndrome according to (NCEP ATP III) = 16 (27%) 
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Gender wise distribution of metabolic syndrome 
 
Metabolic 
Syndrome 
(MetS) 
Number of 
participants(NCEP 
ATP III) 
Percentage 
(NCEP ATP 
III) 
MetS-male 
 
7 20 
MetS- female 
 
9 36 
 
 
50 
 
 
 
 
Gender specific prevalence of metabolic syndrome was also found out 
using NCEP ATP III criteria. Prevalence of metabolic syndrome in was found to  
be 20% in males and 36% in females. Chisquare test was done to find the 
significance of difference. There was no difference between the two groups (p 
value of 0.167). It was inferred that the prevalence of metabolic syndrome was 
higher in females compared to males.    
 
Prevalence based satisfying at least two criteria of metabolic syndrome 
according to NCEP ATP definition 
The table below shows   how many participants meet at least two criteria 
for metabolic syndrome.  Though they may not satisfy the criteria for metabolic 
syndrome, the presence of the risk factors makes them vulnerable for 
cardiovascular and other morbidities associated with metabolic syndrome. 
 
MetS( At least 2 crietria ) Participants Percentage 
MetS+ 28 47 
MetS- 32 53 
Total 60 100 
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Presence of at least one criteria of NCEP ATP definition 
 
51 out of 60 participants had at least one risk factor among the five. 
 
MetS Participants Percentage 
MetS+ 51 85 
MetS- 9 15 
Total 60 100 
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Distribution of variables across genders 
The distribution of various variables across gender was calculated. The 
mean and standard deviation, and a chisquare test were done to assess the 
difference between the groups.  
 
Systolic Blood Pressure 
 
Systolic BP  N Mean SD  F value P value 
Male 35 120 11.1    
2.8 
 
0.097 Female 25 116 11.5 
 
The mean value of systolic blood pressure was higher in males compared 
to females. The difference was not statistically significant. 
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Diastolic blood pressure 
 
Diastolic 
BP 
 N Mean SD  F value P value 
Male 
 
35 77 5.8  
1.69 
 
0.198 
Female 
 
25 75 6 
 
The mean value of diastolic blood pressure was higher in males compared 
to females. The difference was not statistically significant. 
 
Fasting blood sugar 
 
Fasting 
blood sugar 
 N Mean SD  F value P value 
Male 
 
35 89 7.3  
2.58 
 
0.113 
Female 
 
25 96 21 
 
The mean value of fasting blood sugar was higher in females compared to 
males. The difference was not statistically significant. 
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HDL cholesterol 
 
HDL 
cholesterol 
 N Mean SD  F value P value 
Male 
 
35 38 6  
11.6 
 
0.001 
Female 
 
25 46 11.8 
 
The mean value of HDL cholesterol was higher in females compared to males. 
The difference was not statistically significant. 
 
Triglyceride 
 
TG 
 
 N Mean SD  F value P value 
Male 
 
35 147.8 96  
0.054 
 
0.817 
Female 
 
25 142.3 81 
 
The mean value of triglycerides was higher in males compared to females. The 
difference was not statistically significant. 
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Waist circumference 
 
Waist 
circumference 
 N Mean SD  F value P value 
Male 
 
35 94 14  
11.43 
 
0.1 
Female 
 
25 82 22 
 
The mean value of waist circumference was higher in males compared to females. 
The difference was not statistically significant 
 
Presence of at least two components of metabolic syndrome out of five – A 
gender- wise distribution 
 A gender wise distribution of criteria meeting at least two criteria of 
metabolic syndrome is calculated. 
 
Gender MetS(2 criteria)+ No MetS Total 
Male  15 (43%) 20 (57%) 35 
Female 13(52%) 12(48%0 25 
Total 32 (53%) 28 (47%) 60 
 
The prevalence based on at least two components of metabolic syndrome was 
43% in males and 52% in females. The difference was not statistically significant. 
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Prevalence of at least one component of metabolic syndrome out of 5 –  
A gender-wise distribution 
 
Gender  MetS(1 criteria)+  No metS Total 
Male 29(82%) 6 (17%) 35 
Female 22(88%) 3(12%) 25 
Total 51(85%) 9(15%) 60 
 
The prevalence based on at least one component of metabolic syndrome was 82% 
in males and 88% in females. The difference was not   statistically significant. 
 
Distribution according Duration of illness 
The participants were divided into two groups; those who were ill for less 
than one year, and those with illness for more than one year. 
 
Duration of Illness 
 
MetS+ 
(NCEP ATP III) 
MetS- 
(NCEP ATP III) 
Total 
 
Less than  
1 year 
2  9 11 
More than  
1 year 
14 35 49 
Total 
 
16 44 60 
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 Eleven subjects had had been ill for less than one year. Of these, two were 
found to have metabolic syndrome. 14 subjects out of 49, who had been ill for 
more than 1 year, met the criteria for metabolic syndrome. Chisquare test was 
done and no significant difference was found between the two groups(p value of 
0.481). 
 
Distribution according to Duration of antipsychotic use 
We wished to see the effect of the duration of antipsychotic exposure on 
the prevalence of metabolic syndrome. 
 
Duration of 
Antipsychotic use 
 
MetS+ 
(NCEP ATP III) 
MetS- 
(NCEP ATP III) 
Total 
 
Less than  
1 year 
6 23 29 
More than  
1 year 
10 21 31 
Total 
 
16 44 60 
 
The participants were again divided into two groups, based on the total 
duration of antipsychotic drug use. Of 29 subjects on antipsychotic drugs for less 
than one year, 6 were found to have metabolic syndrome. At the same time 10 of 
31, who were on antipsychotic drugs for more than 1 year met the criteria for 
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metabolic syndrome. Chisquare test showed no significant difference with a p 
value of 0.311. 
 
Correlation of antipsychotic exposure to waist circumference 
 
 N Pearson 
correlation 
coefficient 
P value 
Waist 
circumference 
60 -0.041 0.756 
 
There was a negative correlation between duration of antipsychotic exposure and 
waist circumference. However it was not statistically significant. 
 
Correlation of antipsychotic exposure to systolic BP 
 
 N Pearson 
correlation 
coefficient 
P value 
Systolic BP 
 
60 0.118 0.369 
 
There was a positive correlation between duration of antipsychotic exposure and 
systolic blood pressure. However it was not statistically significant. 
 
59 
 
 
Correlation of antipsychotic exposure to diastolic BP 
 
 N Pearson 
correlation 
coefficient 
P value 
Diastolic BP 
 
60 0.219 .0.092 
 
There was a positive correlation between duration of antipsychotic exposure and 
diastolic blood pressure. However it was not statistically significant. 
 
Correlation of antipsychotic exposure to fasting blood sugar 
 
 N Pearson 
correlation 
coefficient 
P value 
AC 
 
60 0.057 0.666 
 
There was a positive correlation between duration of antipsychotic exposure and 
fasting blood sugar. However it was not statistically significant. 
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Correlation of antipsychotic exposure to HDL cholesterol 
 
 N Pearson 
correlation 
coefficient 
P value 
HDL 
 
60 -0.057 0.666 
 
There was a negative correlation between duration of antipsychotic exposure and 
HDL cholesterol. However it was not statistically significant. 
 
 
Correlation of antipsychotic exposure to Triglyceride 
 
 N Pearson 
correlation 
coefficient 
 p value 
TG 
 
60 0.066 0.617 
 
There was a positive correlation between duration of antipsychotic exposure and 
triglyceride. However it was not statistically significant. 
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Correlation of duration of Illness to waist circumference 
 
 N Pearson 
correlation 
coefficient 
P value 
Waist 
circumference 
60 -0.246 0.059 
 
There was a negative correlation between duration of illness and waist 
circumference. However it was not statistically significant 
 
Correlation of duration of illness to HDL cholesterol 
 
 N Pearson 
correlation 
coefficient 
 p value 
HDL 
 
60 0.054 0.681 
 
There was a positive correlation between duration of illness and waist HDL 
cholesterol. However it was not statistically significant. 
 
62 
 
 
 
Correlation of duration of illness to Triglyceride serum 
 
 N Pearson 
correlation 
coefficient 
P value 
Triglyceride 
 
60  0.008 0.954 
 
There was a positive correlation between duration of illness and triglyceride 
serum. However it was not statistically significant. 
 
 
Correlation of duration of illness to systolic BP 
 
 N Pearson 
correlation 
coefficient 
P value 
Systolic BP 
 
60 0.010 0.940 
 
There was a positive correlation between duration of illness and systolic blood 
pressure. However it was not statistically significant. 
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Correlation of duration of illness to diastolic BP 
 
 N Pearson 
correlation 
coefficient 
P value 
Diastolic BP 
 
60 0.088 0.504 
 
 
There was a positive correlation between duration of illness and diastolic blood 
pressure. However it was not statistically significant. 
 
Distribution of metabolic syndrome based on age group 
 
Age group 
 
MetS+ No MetS Total 
Less than 
 40 years 
9 (23%) 31(77%) 40 
More than 
 40 years 
7(35%) 13(65%) 20 
Total 
 
16 36 60 
 
Chisquare value- 1.065       p value- 0.360 
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 Above 40 years of age (35%) had a higher prevalence of metabolic 
syndrome compared to below 40 years of age (23%). The difference was 
statistically not significant 
 
Presence of at least 2 criteria out of 5 based on age group 
 
Age group 
 
MetS+ No metS Total 
Less than  
40 years 
19 (48%) 21(52%) 40 
More than 
 40 years 
9(45%) 11 (55%) 20 
Total 
 
28(53%) 32(47%) 60 
 
Chisquare value- 0.033   p value - 0.537  
The prevalence of at least 2 components of metabolic syndrome was 
higher in those 40 years of age or below (48%) compared to above 40 years of 
age (45%). The difference was statistically not significant. 
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Prevalence of atleast one criteria among 5 based on age group 
 
Age group MetS+ No metS Total 
Less than 
 40 years 
35 (87%) 5(13%) 40 
More than 
 40 years 
16(80%0 4(20%) 20 
Total 
 
51(85%) 9(15%) 60 
 
Chisquare value- 0.588    P value - 0.464 
The prevalence of at least one component of metabolic syndrome was 
higher in above   40 years of age(87%) compared to  below 40 years of age(80%). 
The difference was statistically not significant. 
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DISCUSSION 
 Out of the total participants recruited, 58% were male and 42 % were 
female. The Indian census data 2011 shows that the sex ratio is 940 females per 
1000 males. The data is reflective of the general population trend in our country. 
 According to Indian census data 2011, 74% percent of the population was 
literate. In our study 79% percent of the population was found to be literate. This 
finding is similar to the trend in general population. 
 
 In earlier studies the prevalence of metabolic syndrome in mentally ill 
patients on antipsychotic medication varies from 24 %  to 32% (60–62) 
In our study the overall prevalence of metabolic syndrome 23 % (IDF) and 27% 
(NCEP) has shown that the prevalence of metabolic syndrome was high and 
similar to the earlier studies undertaken. NCEP ATP and IDF have similar criteria 
for metabolic syndrome and take into account the role of abdominal obesity as a 
major factor. Our study has yielded a similar percentage of metabolic syndrome 
using both the criteria.  
 
 Some studies have shown that the prevalence of metabolic syndrome in 
the general population itself is as high as 25 to 30 % (63). Such studies have used 
the same criteria to diagnose the metabolic syndrome. Lack of physical exercise, 
nutritional factors, lifestyle factors and genetic vulnerability are proposed to be 
the major cause of this high prevalence. 
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 The mean age of the participants were found to be 36 in our study. This 
could be due to the fact that schizophrenia is a condition which starts early in life 
and most often is a lifelong condition. The fact that the prevalence of metabolic 
syndrome is slightly low compared to some other studies(62) could be due to the 
fact that the mean age of our population was 36, which is a younger population. 
Other reasons may be that patients were better informed and encouraged to follow 
some physical activities by the treating doctors in this centre where the study was 
conducted. Further studies may be undertaken in this regard to know the 
awareness among patients and relatives regarding metabolic abnormalities and 
importance of diet and exercises. 
         
 The gender specific prevalence of metabolic syndrome was calculated 
according to the NCEP criteria, was found to be higher in females compared to 
males. Earlier studies have shown an equal prevalence of metabolic syndrome in 
males and females(60). However some Indian studies have shown higher 
prevalence of metabolic syndrome in females(63,64).The higher prevalence in 
females could be due to genetic factors as demonstrated in an earlier study(65). 
 
Correlation between duration of antipsychotic use and metabolic syndrome 
 The chance of developing metabolic syndrome is higher when the 
duration of the antipsychotic use increases(60). In our study we found that the 
prevalence of metabolic syndrome is higher in group of patients taking 
medication more than one year as compared to patients taking medications for 
less than a year. The exposure to antipsychotic is an important determining factor 
for the development of metabolic syndrome. The longer the duration of 
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antipsychotic use, the more is the chance of developing metabolic syndrome. It 
could be due to the irreversible metabolic changes due to antipsychotic drugs. 
 
Correlation between duration of illness and metabolic syndrome 
        The prevalence was higher among patients having illness more than one 
year. This could be due to fact that such patients are more likely to have been 
taking medication for a longer duration of time. The disease related factors like 
genetic factors, sedentary life style, and nutritional factors also would have 
contributed to the development of metabolic syndrome over a period of time. The 
effect of lifestyle factors would be more pronounced in this case compared to the 
genetic vulnerability as both the groups are equally vulnerable. A further study 
with a prospective design would help to clearly find out the causative effect of 
duration of mental illness and metabolic syndrome. 
 
        There was no earlier study that looked at the relationship between duration 
of mental illness and risk of metabolic syndrome. 
 
Distribution of individual components of metabolic syndrome 
       Abnormal HDL cholesterol was present in maximum number of participants 
37(62%) followed by increased waist circumference 33(55%), raised triglycerides 
25(42%), raised blood pressure 15(25%) or impaired fasting glucose 8 (13%). It is 
different from a western study which has found  blood pressure(38%), HDL 
(36%) and triglycerides (33%) being the most common components contributing  
metabolic syndrome (64) . The difference could be due to the ethnic and genetic 
differences whereby Indians might be more prone to develop central obesity and 
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lipid abnormalities than hypertension and elevated blood glucose. This suggests 
that criteria sets using waist circumference to detect metabolic syndrome may be 
more valid in the Indian population. 
       
Gender wise correlation of individual components of metabolic syndrome 
       Mean value HDL cholesterol was found to be significantly lower in males 
compared to females. HDL cholesterol is protective against cardiovascular 
complications and atherogenesis. It was similar to a study done in the past(64) . 
This difference could possibly be due to disparity in genetic factors between the 
genders. 
 
       The mean value of waist circumference, triglycerides, and blood pressure 
were higher among males compared to females. At the same time mean value of 
fasting blood sugar was higher in females. However the chisquare test did not 
yield a significant difference between these variables. Studies in the past have 
showed significant difference in the mean values of these components between 
the gender (64).  Our sample size may have had insufficient power to find a 
significant difference between these variables, in this study. 
 
Prevalence of atleast two and at least one component of metabolic syndrome. 
       32 (53%) participants had at least two components of metabolic syndrome 
and 51(85%) participants had at least one component of the metabolic syndrome.  
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       Females (52%) had higher prevalence of at least two components compared 
to males (43%). The prevalence of at least one component of metabolic syndrome 
was higher in females88%) ascompared to males(82%).   
 
       However these differences were not statistically significant. The implication 
of this finding is that the prevalence of individual components of metabolic 
syndrome is alarmingly high in our study population and risk of complications 
due to these could also be high. There were no studies in the past which has 
looked into the prevalence based on the above criteria. 
 
Correlation of duration of antipsychotic exposure and individual components 
of metabolic syndrome. 
       There was a positive correlation with triglycerides, blood pressure and fasting 
blood sugar to duration of antipsychotic exposure. And there was a negative 
correlation with duration of exposure of antipsychotic to HDL cholesterol. 
However these correlations were not significant statistically. Earlier studies have 
shown a positive correlation between duration of antipsychotic exposure and 
metabolic parameters(66). These finding suggest an increase in the risk of 
derangement of metabolic parameters as duration of antipsychotic drug increases. 
A larger sample size may be required to assess this association accurately. 
 
Distribution of metabolic syndrome parameters based on age 
       The prevalence of metabolic syndrome was higher in age group of 40 years 
and above (35%) compared to age group below 40 years (23%). These differences 
were not statistically significant. However, this trend is similar to earlier studies 
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that have shown an increase in the prevalence of metabolic syndrome as age 
increases(67,68).  
 
Strengths of the study 
 
1. The main outcome of the study, prevalence of the metabolic syndrome, 
was calculated using both International Diabetic Federation and National 
Cholesterol Education Program criteria.  
2. Sample of patients selected were from those attending a regular 
psychiatric clinic, reflecting clinical practice in the real world rather than a 
selected research sample. This would improve generalizability. 
  
Limitations of the study 
 
1. Sample size was not achieved.  
2. Results displayed trends similar to previously done studies, but did not 
achieve statistical significance. 
3. The association between the dose of the drug and the metabolic syndrome 
could not be calculated. Although the information about drugs and doses 
were recorded, the lack of medication equivalence figures meant that it 
could not be translated to an analyzable data. 
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Clinical implications 
       The study has found that metabolic syndrome is present in a significant 
proportion of patients receiving antipsychotic medication at a psychiatric clinic in 
South India.  
       Clinicians must be aware of the implications regarding the medication choice 
and the need to take steps to prevent the development of metabolic syndrome in 
their patients.  
       The study also has shown a relation between the duration of antipsychotic 
medication and metabolic syndrome. This has implications about the choice of 
drug since several major mental illnesses require long term antipsychotic use. 
      A higher prevalence of metabolic syndrome in females means that this 
subgroup is more vulnerable to this major complication.   
       It is important to provide patients with information regarding the metabolic 
syndrome and encourage them to do regular physical activity and appropriate diet 
modifications, particularly as a preventive step.  
        Equally important is to identify patients who are more vulnerable to develop 
metabolic syndrome by going through family history and current metabolic status. 
Before starting antipsychotic medications, it is important to record the baseline 
anthropometric data and the laboratory parameters. This would help clinicians to 
identify those more vulnerable to developing metabolic syndrome. It is also 
important to regularly monitor the patients to see if they develop any features of 
metabolic syndrome, by regular physical and laboratory examination.  
       Waist circumference measurement is a simple, inexpensive and sensitive 
measure of risk for metabolic syndrome. 
 
73 
 
 
Future directions 
      Larger sample size studies would provide more robust data to support these 
findings. Prospective studies using a cohort of drug naïve patients would provide 
incidence data. Interventional studies would provide information on the best 
package of management to treat and prevent development of metabolic syndrome.  
 
     This study of metabolic syndrome in those receiving antipsychotics shows that 
large proportions of such patients have deranged physiological functions, with a 
significant subset having a full blown metabolic syndrome. Several have sub 
syndromal conditions. The prevalence matches rates in other studies done. This is 
a clinically relevant finding emphasizing the need for Indian psychiatrists to be 
aware of this side effect and to take preventive action while prescribing 
antipsychotics. 
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SUMMARY 
Introduction 
Metabolic syndrome is a group of risk factors when present in an individual, 
increases the risk of stroke, coronary artery disease and type2 diabetes. There is 
an increased prevalence of metabolic syndrome in mentally ill patients, due to 
sedentary life style factors, medication and genetic causes. 
An extensive literature review has found a paucity of literature on Indian studies 
on the prevalence of metabolic syndrome in mentally ill patients.  
 
Methodology 
 A cross sectional study was done to measure the prevalence of metabolic 
syndrome in patients using antipsychotic medication. Participants, fulfilling the 
inclusion and exclusion criteria, were recruited from the outpatient facility in the 
department of Psychiatry, Christian Medical College, Vellore, after obtaining 
written informed consent. Socio demographic data, anthropometric variables, 
fasting blood glucose, HDL cholesterol and serum triglyceride values were 
measured.  
 
Results 
Analysis was done using 60 participants, prevalence of metabolic syndrome was 
found to be 23%(IDF) and 26%(NCEP). Gender specific prevalence was also 
calculated, with a prevalence of 20% in males and 36% in females. There was no 
significant difference in the prevalence of metabolic syndrome in males and 
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females(p value=0.167). The prevalence of metabolic syndrome was higher in 
patients receiving antipsychotic medication for more than 1 year (p value= 0.311). 
Similarly patients having more than one year duration of illness had a higher 
prevalence of metabolic syndrome(p value= 0.481). The individual components of 
metabolic syndrome also had a higher prevalence in females, however the 
differences were not statistically significant except abnormality in HDL 
cholesterol, which was statistically significant(p value 0.01) 
 
Conclusion 
  The prevalence of metabolic syndrome was found to be high and was 
comparable to the earlier studies. The need has arisen for the clinicians to be more 
cautious while prescribing antipsychotic drugs, anticipate possible development 
of metabolic syndrome, and take necessary steps to prevent the emergence of this 
dreaded complication. 
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APPENDIX 1 
Participant Information Sheet 
“Prevalence of metabolic syndrome in patients receiving 
antipsychotic medication” 
      My name is Dr. Ranjith P and I am doing a research on a 
condition called metabolic syndrome. The research will be done in  
the Department of Psychiatry, CMC, Vellore. 
    Medications can cause various side effects and antipsychotic drugs 
which you are receiving may result weight gain, rise in blood sugar, 
blood pressure and cholesterol.  
     I am aiming to find out these by checking your weight, height and 
testing your blood. I would like to request you to donate  10 ml ( 2 
teaspoonfuls) of blood for use in my study. I will also be collecting 
information regarding your illness from the case record kept in the 
hospital. 
  The blood will be taken using sterile (clean) methods by a trained 
technician. Your information will not be revealed to anyone and all 
information about you and your treatment will be kept confidential.  
     You have every right to refuse to take part in this study. Your 
treatment will not be affected by this.  
APPENDIX 2 
Consent Form 
“Prevalence of metabolic syndrome in patients receiving 
antipsychotic medication” 
    
I..............................................residing in......................................... 
......................give consent  to take part in a study that looks at 
presence of raised blood sugars, cholesterol, blood pressure and 
weight in patients receiving antipsychotic medication. The research 
has been explained to me in the language known to me. I was given 
the chance to ask questions about the study . I have received an 
information sheet as well in my regional language. 
    My treatment will be the same whether I take part in the study or 
not . There is no direct benefit to me because of this study. I will not 
receive any money or gift for taking part in the study other than the 
travel expenses. My personal details will not be disclosed to anyone .I 
have no objection for the study results being published in a scientific 
journal .I can withdraw from the study at any point of this research. 
  Date:                                          Signature of the participant/Thumb 
impression 
 
                                                     Name of the participant 
APPENDIX 3 
Participant Information Sheet - Tamil 
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